Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22008 | 1.00 | — | — | |
| SCHEMBL30609151 | 1.00 | — | — | |
| SCHEMBL31403153 | 0.98 | ATAD2 (0.35) | ATAD2CYP1A2 | |
| Hydrochloric Acid SCHEMBL2199283 | 0.98 | ATAD2 (0.35) | ATAD2CYP1A2 | |
| SCHEMBL30917957 | 0.98 | ATAD2 (0.35) | ATAD2CYP1A2 | |
| Water SCHEMBL28196064 | 0.98 | ATAD2 (0.35) | ATAD2CYP1A2 | |
| SCHEMBL15571194 | 0.90 | ATAD2 (0.31) | ATAD2 | |
| Phosphoric Acid SCHEMBL17185718 | 0.90 | ADORA2A (0.32) | ATAD2CYP1A2 | |
| Phosphoric Acid SCHEMBL7587250 | 0.90 | ADORA2A (0.32) | ATAD2CYP1A2 | |
| Sulfuric Acid SCHEMBL28173989 | 0.90 | ATAD2 (0.31) | ATAD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114106125-B | Ginkgo peptide, special medical formula food containing ginkgo peptide and application of ginkgo peptide | 大连海洋大学 | 2023-08-08 | — | — | CN | disclosed |
| CN-114106125-A | Ginkgo peptide, special medical formula food containing same and application thereof | 大连海洋大学 | 2022-03-01 | — | — | CN | disclosed |
| CN-110431227-A | Novel integration site and application thereof | APPLIED STEMCELL INC | 2019-11-08 | — | — | CN | disclosed |
| EP-3150727-B1 | RNASE-H-BASED ASSAYS UTILIZING MODIFIED RNA MONOMERS | INTEGRATED DNA TECH INC (US) | 2019-07-10 | — | — | EP | disclosed |
| US-10227641-B2 | RNase H-based assays utilizing modified RNA monomers | INTEGRATED DNA TECHNOLOGIES, INC. (US) | 2019-03-12 | — | — | US | disclosed |
| US-20190002865-A1 | RNase H-Based Assays Utilizing Modified RNA Monomers | INTEGRATED DNA TECHNOLOGIES, INC. | 2019-01-03 | — | — | US | disclosed |
| US-20170355978-A1 | RNase H-Based Assays Utilizing Modified RNA Monomers | INTEGRATED DNA TECHNOLOGIES, INC. | 2017-12-14 | — | — | US | disclosed |
| US-9644198-B2 | RNase H-based assays utilizing modified RNA monomers | INTEGRATED DNA TECHNOLOGIES, INC. (US) | 2017-05-09 | — | — | US | disclosed |
| EP-3150727-A1 | RNASE-H-BASED ASSAYS UTILIZING MODIFIED RNA MONOMERS | Integrated DNA Technologies Inc. (US) | 2017-04-05 | — | — | EP | disclosed |
| EP-2644710-B1 | RNASE-H-BASED ASSAYS UTILIZING MODIFIED RNA MONOMERS | INTEGRATED DNA TECH INC (US) | 2016-12-21 | — | — | EP | disclosed |
| EP-2644707-A1 | RNase-H-based assays utilizing modified RNA monomers | Integrated Dna Technologies, Inc. (US) | 2013-10-02 | — | — | EP | disclosed |
| EP-2644708-A1 | RNASE-H-based assays utilizing modified RNA monomers | Integrated Dna Technologies, Inc. (US) | 2013-10-02 | — | — | EP | disclosed |
| EP-2644710-A1 | RNase-H-based assays utilizing modified RNA monomers | Integrated Dna Technologies, Inc. (US) | 2013-10-02 | — | — | EP | disclosed |
| EP-2279263-B1 | RNASE-H-BASED ASSAYS UTILIZING MODIFIED RNA MONOMERS | INTEGRATED DNA TECH INC (US) | 2013-09-04 | — | — | EP | disclosed |
| US-20120258455-A1 | RNase H-Based Assays Utilizing Modified RNA Monomers | INTEGRATED DNA TECHNOLOGIES, INC. (US) | 2012-10-11 | — | — | US | disclosed |
| WO-2012135053-A2 | RNASE H-BASED ASSAYS UTILIZING MODIFIED RNA MONOMERS | INTEGRATED DNA TECHNOLOGIES, INC. (US) | 2012-10-04 | — | — | WO | disclosed |
| EP-2279263-A2 | RNASE-H-BASED ASSAYS UTILIZING MODIFIED RNA MONOMERS | Integrated Dna Technologies, Inc. (US) | 2011-02-02 | — | — | EP | disclosed |
| US-20100167353-A1 | RNASE H-BASED ASSAYS UTILIZING MODIFIED RNA MONOMERS | INTEGRATED DNA TECHNOLOGIES, INC. (US) | 2010-07-01 | — | — | US | disclosed |
| US-20090325169-A1 | RNASE H-BASED ASSAYS UTILIZING MODIFIED RNA MONOMERS | INTEGRATED DNA TECHNOLOGIES, INC. (US) | 2009-12-31 | — | — | US | disclosed |
| WO-2009135093-A2 | RNASE-H-BASED ASSAYS UTILIZING MODIFIED RNA MONOMERS | INTEGRATED DNA TECHNOLOGIES, INC. (US) | 2009-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325169-A1 | RNASE H-BASED ASSAYS UTILIZING MODIFIED RNA MONOMERS | RNASEH1, RNASEL, RNASE1 | ATAD2 1875/4885CYP1A2 4317/4885NOTUM 1772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.